Sobi and Pfizer have extended their supply agreement for ReFacto AF®/XYNTHA®
until 31 December 2020, with an option to be further renewed. The previous
agreement was due to expire in 2015.
Sobi will continue to be the global supplier of the drug substance for ReFacto
AF®/XYNTHA®, which is produced in the company's plant in Stockholm.
In a separate agreement, Sobi and Pfizer have agreed that Sobi will return the
co-promotion rights for ReFacto® and BeneFIX® in the Nordic region to Pfizer as
of 15 February 2012 in exchange for a payment to Sobi in the amount of USD 47.5
M.
Sobi's total revenues from ReFacto AF®/XYNTHA® in the first nine months of 2011
amounted to SEK 542 M, of which manufacturing accounted for SEK 374 M, royalties
for SEK 95 M and co-promotion for SEK 73 M. Sobi's agreement regarding royalties
from Pfizer's global sales of ReFacto AF®/XYNTHA® is unchanged.
"We are very pleased to extend the term of our supply agreement and to continue
this long and successful partnership with Pfizer. Simplifying our relationship
around the commercialization of ReFacto® and BeneFIX® will also enable Sobi to
focus on building its own presence in the hemophilia area," says Geoffrey
McDonough, President and CEO of Sobi.
About ReFacto AF®/XYNTHA®
ReFacto AF®/XYNTHA® is a recombinant protein drug for treatment of hemophilia A.
In this form of bleeding disorder, the blood's ability to coagulate is
compromised due to a deficiency of coagulation factor VIII in the blood.
Uncontrolled internal bleeding may produce pain and swelling as well as
permanent damage, especially in joints. Injections of factor VIII and proper
health care allow most persons with hemophilia A to live a normal life. ReFacto
AF® is the trademark for the product in Europe and XYNTHA® is the registered
trademark in the US, Canada, Australia and other select global markets. BeneFIX®
is a recombinant protein drug for treatment of hemophilia B and the deficiency
of coagulation factor IX.
Telephone conference
CEO Geoffrey McDonough and CFO Lars Sandström will be available for questions at
9.30 a.m. CET. Please call:
Sweden: +46 (0)8 505 598 09
UK: +44 (0)207 750 9950
USA: +1 866 676 58 69
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 60 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ
Stockholm. More information is available atwww.sobi.com.
The information above has been published pursuant to the Swedish 3 Market Act
and/or the Financial Instruments Trading Act. The information was released for
public distribution on 16 February 2012 at 08.30 a.m. CET.
[HUG#1586376]
